PT - JOURNAL ARTICLE AU - James A. Poulter AU - Alesia Khan AU - Stephen Martin AU - Mark Grey AU - Bosko Andjelic AU - Emma Nga AU - Diana I.D. Triantafyllopoulou AU - Paul Evans AU - Louise Sorensen AU - Sarah L. Mackie AU - UKGCA Consortium AU - Ann W. Morgan AU - Catherine Cargo AU - Sinisa Savic TI - A high-throughput amplicon screen for somatic <em>UBA1</em> variants in Cytopenic and Giant Cell Arteritis cohorts AID - 10.1101/2021.12.08.21266919 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.08.21266919 4099 - http://medrxiv.org/content/early/2021/12/08/2021.12.08.21266919.short 4100 - http://medrxiv.org/content/early/2021/12/08/2021.12.08.21266919.full AB - Somatic mutations in the gene encoding the major E1 ubiquitin ligase, UBA1, were recently identified as a cause of VEXAS, a late-onset acquired auto-inflammatory syndrome. Differential diagnoses for patients subsequently found to have VEXAS include relapsing polychondritis, Sweet’s syndrome, myelodysplastic syndrome (MDS), giant cell arteritis (GCA) and undifferentiated systemic autoinflammatory disease (uSAID). We therefore sought to screen DNA from individuals with a non-diagnostic cytopenia or GCA, for known VEXAS-associated mutations. To this end, we developed a multiplexed UBA1 amplicon sequencing assay, allowing quick screening of large cohorts while also providing sufficient sequencing depth to identify somatic mutations to an allele frequency &lt;1%. Using this assay, we screened genomic DNA from 612 males diagnosed with GCA, and bone marrow DNA from 1,055 cases with an undiagnosed cytopenia. No GCA cases were found to have UBA1 mutations, however 4 different mutations in the cytopenic cohort were identified in 7 individuals. Furthermore, we describe a female case identified in the screen with a UBA1 mutation and all VEXAS-associated phenotypes, but without Monosomy X. Our study suggests that, despite the overlap in clinical features, VEXAS is rarely misdiagnosed as GCA, but identified in 1.0% of males with an undiagnosed cytopenia. The identification of a UBA1 variant in a female case adds further evidence that VEXAS should not be ruled out as a differential diagnosis in females with VEXAS-like symptoms.Key points- Mutations in UBA1 exon 3 have been associated with VEXAS syndrome- UBA1 exon 3 was screened in 1650 patients with cytopenia or GCA by amplicon sequencing.- 6 males were identified from the non-diagnostic cytopenia cohort (1.0%) with UBA1 mutations.- A female with a somatic UBA1 mutation was identified without Monosomy XCompeting Interest StatementCC has contributed to advisory boards for Novartis and AOP Orphan and has research funding from Celgene. PE has received honoraria from Astellas. The remaining authors declare no conflicts of interest.Funding StatementJ.A.P is supported by a UKRI Future Leaders Fellowship (MR/T02044X/1). GCA research is also supported by an MRC Treatment According to Response in Giant cEll arteritis (TARGET) Partnership award to AWM and is supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre and a NIHR Senior Investigator award to AWM. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was partially funded by unrestricted research grant from SOBI pharmaceuticals.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All cytopenia samples were taken with full-informed patient consent for investigation of a suspected haematological disorder. The North East - York Research Ethics Committee gave ethical approval for this work (REC ref: 16/NE/0105). For the GCA cohort, the Leeds West Research Ethics Committee gave ethical approval for this work (REC ref: 05/Q1108/28).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. Sequence data have been submitted and are available from NCBI Sequence Read Archive (ref. PRJNA784094).